Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting
predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical …

Onconephrology is a new subspecialty of nephrology that recognizes the important
intersections of kidney disease with cancer. This intersection takes many forms and includes …

Drug-induced thrombotic microangiopathy (DITMA) represents 10%–13% of all thrombotic
microangiopathy (TMA) cases and about 20%–30% of secondary TMAs, just behind …

Secondary hemolytic uremic syndrome (HUS) is a heterogeneous group of thrombotic
microangiopathies associated with various underlying conditions. Whether it belongs to the …

Thrombotic microangiopathy (TMA) is a rare but severe disorder characterized by
endothelial cell activation and thrombus formation. It manifests with the triad of hemolytic …

Conventional chemotherapies remain the mainstay of treatment for many malignancies.
Kidney complications of these therapies are not infrequent and may have serious …

The demand for cardiac surgery is constantly growing worldwide for reasons of increasing
incidence of degenerative and lifestyle diseases, and rheumatic heart conditions. Presently …

Cancer patients may develop a variety of kidney lesions that impair not only their immediate
survival but also limit the adequate treatment of the underlying malignant process. This …

Thrombotic thrombocytopenic purpura (TTP) is a rare hematologic disorder (annual
incidence of 11.3 cases per 1 million population), characterized by microangiopathic …

Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome
(HUS) are appropriately at the top of a clinician's differential when a patient presents with a …